|
DCAF5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.28809996002843E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.25240000381899E-08 |
| Normal-vs-Stage2 |
1.263280E-03 |
| Normal-vs-Stage3 |
3.98790001021609E-09 |
| Normal-vs-Stage4 |
3.37609999956356E-08 |
| Stage1-vs-Stage2 |
4.257200E-01 |
| Stage1-vs-Stage3 |
6.095500E-02 |
| Stage1-vs-Stage4 |
9.416400E-02 |
| Stage2-vs-Stage3 |
5.744300E-02 |
| Stage2-vs-Stage4 |
5.638500E-02 |
| Stage3-vs-Stage4 |
8.418400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.41439995668702E-09 |
| Normal-vs-AfricanAmerican |
8.304500E-03 |
| Normal-vs-Asian |
2.008700E-04 |
| Caucasian-vs-AfricanAmerican |
3.029800E-01 |
| Caucasian-vs-Asian |
4.020400E-01 |
| AfricanAmerican-vs-Asian |
7.148400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.92539999949371E-07 |
| Normal-vs-Female |
1.79949999346007E-09 |
| Male-vs-Female |
6.095200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.46499999487926E-08 |
| Normal-vs-Age(41-60Yrs) |
1.37959999979564E-07 |
| Normal-vs-Age(61-80Yrs) |
5.72520000297061E-08 |
| Normal-vs-Age(81-100Yrs) |
6.763800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.580400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.766800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.621190E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.409000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.957000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.003600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.71969999999533E-05 |
| Classical-VS-Follicular |
3.370400E-01 |
| Classical-VS-Other |
4.470000E-01 |
| Classical-VS-Normal |
1.54680000030716E-07 |
| Tall-VS-Follicular |
6.960500E-03 |
| Tall-VS-Other |
2.395200E-01 |
| Tall-VS-Normal |
1.69079972245356E-10 |
| Follicular-VS-Other |
7.426600E-01 |
| Follicular-VS-Normal |
4.52439999998333E-06 |
| Other-VS-Normal |
1.179870E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.10170000011678E-07 |
| Normal-vs-N1 |
1.54382999999481E-05 |
| N0-vs-N1 |
6.634800E-01 |
|
|
